Endonovo Therapeutics, Inc. (ENDV) to Acquire Rio Grande Neurosciences

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Endonovo Therapeutics, Inc. (OTC: ENDV) announced it has executed a binding letter of intent (LOI) to acquire Rio Grande Neurosciences, Inc. (RGN), a privately-held clinical stage developer of non-invasive Electroceuticals™ for the treatment of neuro-inflammation and central nervous system diseases and disorders. The LOI is binding, but subject to the execution of a definitive purchase agreement, shareholder approvals from both companies and Endonovo raising additional capital. The parties expect to sign a definitive agreement within the third quarter ending September 30, 2016 and close at the same time or shortly thereafter. Endonovo has paid $500,000 towards the purchase price through the issuance of a note. Pursuant to the LOI, Endonovo will be…


Link to Full Article: Endonovo Therapeutics, Inc. (ENDV) to Acquire Rio Grande Neurosciences